We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

253 hedge funds and large institutions have $1.92B invested in CRISPR Therapeutics in 2019 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 68 increasing their positions, 52 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 18

70% more capital invested

Capital invested by funds: $1.13B → $1.92B (+$791M)

39% more funds holding

Funds holding: 182 → 253 (+71)

31% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 52

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

2.91% more ownership

Funds ownership: 50.39% → 53.3% (+2.9%)

4% less call options, than puts

Call options by funds: $55.6M | Put options by funds: $58.2M

Holders
253
Holders Change
+71
Holders Change %
+39.01%
% of All Funds
4.99%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.12%
New
91
Increased
68
Reduced
52
Closed
18
Calls
$55.6M
Puts
$58.2M
Net Calls
-$2.58M
Net Calls Change
-$3.6M

Top Buyers

1
Ameriprise
Ameriprise
Minnesota
+$24.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.5M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$21.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.7M
5
Two Sigma Investments
Two Sigma Investments
New York
+$19.8M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$15.3M
2
OTPPB
Ontario Teachers' Pension Plan Board
Ontario, Canada
-$13.2M
3
FCM
Farallon Capital Management
California
-$11.5M
4
AC
Armistice Capital
New York
-$6.33M
5
Wells Fargo
Wells Fargo
California
-$6.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
1
Versant Venture Management
California
$256M -$1.54M -28,255 -0.7%
NAMA
2
Nikko Asset Management Americas
New York
$186M +$14.9M +272,139 +10%
AIM
3
ARK Investment Management
Florida
$180M +$9.53M +174,495 +6%
NMC
4
NEA Management Company
Maryland
$127M – – –
Federated Hermes
5
Federated Hermes
Pennsylvania
$76.8M +$21.8M +400,037 +46%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$67.6M +$22.5M +411,929 +59%
WRF
7
Waddell & Reed Financial
Kansas
$62.6M -$1.04M -19,008 -2%
CAM
8
Cormorant Asset Management
Massachusetts
$60.9M -$4.6M -84,300 -8%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$58M +$21.7M +398,012 +72%
O
10
OrbiMed
New York
$46.7M +$13.6M +249,978 +48%
BG
11
Bellevue Group
Switzerland
$44.5M -$5.83M -106,700 -13%
CS
12
Credit Suisse
Switzerland
$43.9M -$465K -8,516 -1%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$42.6M -$15.3M -280,556 -29%
BlackRock
14
BlackRock
New York
$38.3M +$700K +12,827 +2%
A
15
Abingworth
United Kingdom
$31.6M -$5.96M -109,200 -17%
Ameriprise
16
Ameriprise
Minnesota
$28.6M +$24.5M +449,202 +2,184%
Two Sigma Investments
17
Two Sigma Investments
New York
$28M +$19.8M +362,978 +378%
CCP
18
Clough Capital Partners
Massachusetts
$27.1M -$1.9M -34,876 -7%
Franklin Resources
19
Franklin Resources
California
$26.5M +$602K +11,031 +3%
Wells Fargo
20
Wells Fargo
California
$24.8M -$6.2M -113,523 -22%
Renaissance Technologies
21
Renaissance Technologies
New York
$24M +$19.4M +355,264 +904%
Capital International Investors
22
Capital International Investors
California
$22.8M +$12.9M +237,000 +172%
GTP
23
Global Thematic Partners
New York
$21.3M +$315K +5,764 +2%
FCM
24
Farallon Capital Management
California
$21.3M -$11.5M -210,367 -38%
Millennium Management
25
Millennium Management
New York
$19M +$11.2M +205,895 +193%
1
2 3 4 5

CRSP Hedge Fund Activity: Q4 2019 in Review

253 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2019, worth a combined $1.92B — up 70% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new CRSP positions and 18 closed out — a net gain of 73 holders — while 68 added to existing stakes and 52 trimmed.

The largest buyer was Ameriprise, adding an estimated $24.5M. The largest seller was Wellington Management Group, cutting an estimated $15.3M.

  • 253 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2019, up from 182 in Q3 2019.
  • Funds reported $1.92B of CRISPR Therapeutics stock for Q4 2019, up 70% quarter-over-quarter.
  • 91 funds opened new CRISPR Therapeutics positions in Q4 2019 and 18 closed out, a net change of +73 holders.
  • The largest CRISPR Therapeutics buyer in Q4 2019 was Ameriprise, an estimated $24.5M added.
  • The largest CRISPR Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $15.3M sold.

Based on aggregated 13F filings for Q4 2019.